SEC Company Response from Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328) (SBFM) — Jul 21, 2014
Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328)
Date: July 21, 2014 · CIK: 0001402328 · Accession: 0001354488-14-003723
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196191
Letter
Securities and Exchange Commission Sunshine Biopharma, Inc.; Form S-1; SEC File No. 333-196191
RE:
Dear Ms. Hunter:
The undersigned, on behalf of Sunshine Biopharma, Inc. (the “Company”), hereby requests that the United States Securities and Exchange Commission issue an Order of Effectiveness by acceleration to the Company’s above referenced registration statement on Form S-1, with an effective date and time of Wednesday, July 23, 2014, at 9:00 a.m. Eastern Time (7:00 a.m. Mountain Time).
As there is no underwriter for this offering, no consent of any FINRA member is required. In addition, in the event this date and time is not acceptable to the staff of the Commission, we would request that the staff accept oral requests for acceleration from the undersigned or our legal counsel, Andrew I. Telsey, Esq.
In addition, please be advised that:
(a) The Undersigned acknowledges that the Company is responsible for the adequacy and accuracy of the disclosure in its filings, including, but not limited to, the above referenced filing;
(b) the staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filings; and
(c) we acknowledge that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
SUNSHINE BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
sbfm_corresp.htm
July 21, 2014
VIA: EDGAR
Securities and Exchange Commission
450 Fifth Street, N. W.
Washington, D.C. 20549
Attn: Sandra Hunter, Esq.
RE:
Sunshine Biopharma, Inc.;
Form S-1;
SEC File No. 333-196191
Dear Ms. Hunter:
The undersigned, on behalf of Sunshine Biopharma, Inc. (the “Company”), hereby requests that the United States Securities and Exchange Commission issue an Order of Effectiveness by acceleration to the Company’s above referenced registration statement on Form S-1, with an effective date and time of Wednesday, July 23, 2014, at 9:00 a.m. Eastern Time (7:00 a.m. Mountain Time).
As there is no underwriter for this offering, no consent of any FINRA member is required. In addition, in the event this date and time is not acceptable to the staff of the Commission, we would request that the staff accept oral requests for acceleration from the undersigned or our legal counsel, Andrew I. Telsey, Esq.
In addition, please be advised that:
(a) The Undersigned acknowledges that the Company is responsible for the adequacy and accuracy of the disclosure in its filings, including, but not limited to, the above referenced filing;
(b) the staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filings; and
(c) we acknowledge that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
SUNSHINE BIOPHARMA, INC.
s/ Dr. Steve Slilaty
Dr. Steve Slilaty
Chief Executive Officer
cc Andrew I. Telsey, Esq.